Nektar Therapeutics (NKTR) Total Debt (2011 - 2020)

Nektar Therapeutics' Total Debt history runs 10 years deep, the most recent figure standing at $508.9 million for Q1 2020.

• On a quarterly basis, Total Debt rose 105.73% year-over-year to $508.9 million in Q1 2020; TTM through Mar 2020 was $508.9 million, a 105.73% increase from a year earlier, with the FY2019 full-year figure at $252.9 million, up 2.41% from the prior year.
• Total Debt advanced to $508.9 million in Q1 2020 per NKTR's latest filing, from $252.9 million in the prior quarter.
• Across five years, Total Debt topped out at $508.9 million in Q1 2020 and bottomed at $242.1 million in Q1 2016.
• The 5-year median for Total Debt is $245.6 million (2018), against an average of $261.2 million.
• Across the five-year window, Total Debt climbed 0.71% in 2019 and soared 105.73% in 2020, its largest moves.
• Year by year, Total Debt stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then advanced by 2.41% to $252.9 million in 2019, then soared by 101.25% to $508.9 million in 2020.
• Per Business Quant, the three latest NKTR Total Debt figures stand at $508.9 million (Q1 2020), $252.9 million (Q4 2019), and $248.3 million (Q3 2019).